Based on these results and surviving ambassadorial statistics, the products be deem apposite for unbroken encouragement by means of a topical microbicide for the limit of HIV and genital herpes (HSV) and the exploration of other approaching expression. These findings backbone up at the same time and forthcoming clinical study to rasping calculation the refuge and efficacy of VivaGel(R) for genital herpes and HIV in sexually stirring women.
Pacific Specialists, with office in Los Angeles and Marina del Rey, California, be formed in 2002 with the first institute of influential floorboard certified expert, Cadvan O. Griffiths MD, LLB., Chester F. Griffiths MD, FACS, Howard R. Krauss, MD and Gregory Frazer, AuD, PhD. Pacific Specialists be formulate of Pacific Eye & Ear, Pacific Head & Neck, Pacific Cosmetic Surgeons, Pacific Hearing & Balance, and West Wilshire Medical Surgical Center. Specialties cover Otolaryngology, Ophthalmology, Neurosurgical Ophthalmology, Otology, Audiology and Plastic and Reconstructive Surgery.
About Merck/Schering-Plough Pharmaceuticals Merck/Schering-Plough Pharmaceuticals is a joined activity linking Merck & Co., Inc. and Schering-Plough Corporation formed to pull your socks up and open market in the United States strange prescription pills in cholesterol guidance. The support was expanded to reckon large-scale market (excluding Japan).
Merck Forward-Looking Statement: This clasp giving out cover "forward-looking statements" through that hall is defined in the Private Securities Litigation Reform Act of 1995. These statement mean risk and uncertainties, which may cause grades to wander materially from those defined forth in the statements. The forward-looking statements may include statements about commodities flutter, product approaching or economic celebration. No forward-looking dispatch note can be guaranteed, and actual results may differ materially from those projected. Merck engage in no necessity to publicly update any forward-looking statement, whether therefore of new statistics, impending events, or otherwise. Forward-looking statements here press release should be evaluated in cooperation with the frequent uncertainties that affect Merck's company, outstandingly those introduce in the intimidating statements in Item 1 of our Form 10-K for the year concluded Dec. 31, 2003, and in our finished up reports by the side of Form 10-Q and Form 8-K (if any), which the drove take in by hint.
Schering-Plough Disclosure Notice: This press release contains "forward-looking statements" inwardly the classification of the Securities Litigation Reform Act of 1995, together with the market for VYTORIN. Forward-looking statements recount to expectations or forecasts of future events and not to historical information. Schering-Plough carry out not suppose the obligation to update any forward-looking statement. There be no guarantee gruffly the market performance of VYTORIN, Schering-Plough smallholding animals or Schering-Plough's business. Actual results may alter materially from forward-looking statements made here or in other Schering-Plough documentary or unwritten communications in the red to many factor and uncertainties, which include the market assumption of VYTORIN, import buying stencil, the pilot remarks and performance of aggressive products in the market, legislation that may impact the pricing/availability of VYTORIN and other items deliberate in Schering-Plough's Securities and Exchange Commission filings, including the company's 8-K profile October 21, 2004, and future SEC filings.
cross-sectional study of movie smoking and teen smoking.
Denise Foy, 908-298-7616 or Investor: Merck & Co., Inc.
Michael Rabinowitz, 908-423-5185 Schering-Plough Corp.
Alex Kelly Janet Barth 908-298-7436
Medicine herbal medicine - new features.
0 comments:
Post a Comment